The Spravato monitoring challenge
Spravato (esketamine nasal spray) requires patients to be monitored in-clinic for at least 2 hours after each administration under the REMS program. That’s rigorous, protocol-driven monitoring, for 2 hours out of every 168 in a week.
What happens in the other 166 hours is largely invisible to the prescribing clinician. Patients go home. They sleep, work, interact with family, have good days and bad days. Their response to esketamine, or the beginning of relapse, plays out entirely outside the clinic window.
The standard monitoring approach between REMS sessions involves PHQ-9 or MADRS assessments at scheduled intervals, supplemented by whatever the patient self-reports at the next session. Both have the same fundamental limitation: they capture a single point in time, depend on patient recall and self-awareness, and miss the between-session dynamics that determine treatment trajectory.
The esketamine response durability problem
Esketamine response is real, but it’s not permanent. The TRANSFORM studies showed a rapid-onset antidepressant effect, but response durability varies significantly. Some patients maintain response well through the maintenance phase; others show gradual degradation between sessions that goes undetected until symptoms become severe. Continuous monitoring is the only way to catch that degradation early.
The discontinuation cliff
The single most important fact about Spravato program economics is this: most patients don’t stay on treatment long enough to benefit fully.That statement is not a suspicion; it’s the finding of two large real-world datasets published in the last two years.
ESKALE cohort (France)
79.6%
of Spravato patients discontinue within 12 months
Real-world pharmacovigilance cohort. Only ~15% of discontinuations were driven by adverse events. The rest were logistical, motivational, or loss-of-response.
Komodo claims (US)
8.2 mo
median time to discontinuation
Across a large commercial claims dataset. Induction alone takes 64 days on average (vs. 28 days prescribed), so a meaningful share of the maintenance window is spent just finishing induction.
Where the patients go
- ~15%AE-driven; the REMS program already catches these
- ~25%Logistical: commute, scheduling, cost-sharing, prior-auth churn
- ~40%Silent loss of response: patient tells the clinic they feel "okay," stops booking
- ~20%Partial / plateau responders: sub-threshold benefit, unclear next step
Distribution synthesized from ESKALE + Komodo reporting. Every category except AE-driven is visible in behavioral signal weeks before the patient silently drops.
Reinitiation works: the SUSTAIN-3 long-term extension data (Castro et al. 2023) showed meaningful re-response when patients who had discontinued came back for retreatment. The problem is that most don’t come back at all. They’re not re-treated because nobody knows they’re deteriorating.
This is the discontinuation cliff. It’s where the maintenance-phase economics of a Spravato program either work or don’t. And it’s almost entirely invisible from inside the clinic.
Spravato REMS monitoring requirements
Spravato (esketamine) is dispensed only through a restricted FDA Risk Evaluation and Mitigation Strategy (REMS) program. The REMS defines what you must monitor inside the clinic on dosing days, but it is silent on the days in between — which is exactly where most outcome signal is lost.
The core in-clinic Spravato monitoring requirements are:
- Supervised administration. Each dose is self-administered under the direct observation of a healthcare provider in a certified healthcare setting. The drug is never dispensed for home use.
- Minimum 2-hour post-dose monitoring. Patients are monitored for at least two hours after each dose for sedation, dissociation, and blood-pressure changes before they can be discharged.
- Blood pressure assessment. Blood pressure is checked before dosing and again at roughly 40 minutes, then as clinically indicated, because esketamine can cause transient increases.
- No driving until next day. Patients must arrange transport and may not drive or operate machinery until they have had a full night's sleep.
- Certified site and patient enrollment. Both the healthcare setting and every patient must be enrolled in the Spravato REMS, with dosing documented for each session.
These requirements protect patients during and immediately after dosing. What they do not do is tell you how a patient is responding across the 6–8 weeks of induction and into maintenance. That between-session window is unmonitored by design — and it is where relapse and discontinuation begin.This is general educational information, not regulatory or clinical advice. Always follow the current FDA Spravato REMS and your institution’s protocols.
What happens between REMS sessions
Three patterns emerge in Spravato patients that are only visible through continuous monitoring:
Responders with durable response
Depression index remains stable or continues declining between sessions. These patients are on the right trajectory. Their data shows this; without a monitoring tool, you’re relying on patient self-report at each session visit.
Action: Continue protocol, use data to support REMS documentation
Partial responders with between-session decay
Depression index drops immediately after session (acute effect) but rebounds toward baseline before the next session. These patients may report feeling 'fine' at their REMS visit because they’re experiencing the post-session peak. The between-session decay is invisible without continuous monitoring.
Action: Consider session frequency, adjunctive therapy, or protocol modification
Non-responders trending toward dropout
No sustained depression index improvement across multiple sessions. These patients are at the highest risk of discontinuing the program, either because of lack of perceived benefit or because a relapse drives them out. Early identification allows protocol reassessment before dropout occurs.
Action: Clinical review, protocol modification, or escalation discussion
Objective outcome measurement
Spravato programs are under increasing scrutiny from payers and regulatory bodies to demonstrate measurable treatment outcomes. PHQ-9 scores at session visits provide a compliance data point, but they don’t tell the story of what’s happening between sessions.
Objective, continuous outcome measurement addresses three distinct clinical needs in a Spravato program:
Treatment response documentation
Continuous depression index data provides objective evidence of treatment response across the full treatment period, not just at scheduled assessment points.
Dosing optimization
Between-session decay patterns inform session frequency decisions. Is twice-weekly induction producing durable benefit? Is the maintenance schedule appropriate?
Early dropout prevention
Patients who are not responding tend to disengage before formally discontinuing. Early detection creates an intervention window.
Passive monitoring for Spravato patients
Passive monitoring integrates into a Spravato program without changing any existing clinical workflows. The patient installs EmoDTx once (ideally at the initial REMS enrollment visit), and the app runs passively from that point forward.
The depression index score updates every 24 hours. For a Spravato patient, this creates a complete picture of the between-session trajectory: what happened the day after their last session, the midpoint, the day before the next session. That’s clinical data that doesn’t exist anywhere else.
A Spravato patient’s 84-day monitoring window
Passive monitoring runs continuously across all phases, capturing the full response trajectory
r=0.89
Correlation with MADRS
48h
Relapse early warning
80%
Patient activation rate
4×
Documented net ROI in IP clinics
Practice ROI and billing considerations
A Spravato patient represents significant revenue: each induction session generates infusion fees, and a patient who completes the maintenance phase represents a multi-month revenue stream. Patient attrition during treatment is the primary revenue risk in a Spravato program.
The 4× documented net ROI from passive monitoring in interventional psychiatry clinics is driven primarily by one mechanism: preventing the 60% of relapses that currently go undetected, and with them, the patients who disappear from the program. For a Spravato patient, catching a relapse early means keeping a patient in a program worth $15,000–$30,000 in treatment revenue per year.
| Scenario | Revenue impact |
|---|---|
| Patient completes full induction + 12-month maintenance | +$18,000–$28,000 |
| Patient detected relapsing early, retained | +$12,000–$20,000 |
| Patient relapses undetected, drops out | –$15,000–$25,000 |
| Net revenue difference (early detection vs. dropout) | +$27,000–$45,000 |
Estimates based on average Spravato program economics. Actual figures vary by practice, payer mix, and geographic market.
Implementation workflow
Integrating passive monitoring into an existing Spravato program takes one staff member one afternoon to configure. There is no EHR integration, no IT project, no REMS workflow modification.
Clinic setup
Configure portal.emobothealth.com for your practice. Add your clinical team. Set alert thresholds. Takes 30 minutes.
Patient enrollment (new patients)
Enroll new Spravato patients at their first REMS session. Walk through EmoDTx setup on their phone (3 min). Explain: 'This monitors your wellbeing between sessions; you don't have to do anything.'
Enroll existing patients
Introduce EmoDTx to existing patients at their next scheduled session. Proposing it and installing it with the patient in the visit drives 80% activation. Most patients are positive about passive monitoring; they want to know if their treatment is working.
Pre-session dashboard review
Clinical coordinator reviews dashboard before each session. Any patient with a downward trend gets flagged for the prescribing physician. Patients with stable or improving trends get a different conversation.
References
Discontinuation, induction timing, and retreatment figures on this page trace back to named real-world cohorts and peer-reviewed trials.
- ESKALE cohort. Real-world effectiveness and discontinuation of esketamine nasal spray in treatment-resistant depression, French pharmacovigilance study. PMC 11919239 (2024). 79.6% discontinuation within 12 months; ~15% AE-driven.
- Komodo Health claims analysis. US commercial dataset on esketamine induction and maintenance utilization. Median time to discontinuation 8.2 months; median induction completion 64 days vs. 28 prescribed.
- Castro M, et al. Long-term efficacy and safety of esketamine nasal spray in patients with treatment-resistant depression: SUSTAIN-3. Am J Psychiatry. 2023. (Reinitiation efficacy in patients returning after discontinuation.)
- SPRAVATO REMS Program. Risk Evaluation and Mitigation Strategy.Post-marketing surveillance, N = 58,483 patients. 77% adverse events of special interest; 7.7–9.5% AE-driven discontinuation.
- Janssen Pharmaceuticals. TRANSFORM-1, TRANSFORM-2, TRANSFORM-3.Pivotal efficacy trials for esketamine nasal spray in TRD.
Emobot’s own validation (MADRS r=0.89, PHQ-9 r=0.83, 10+ peer-reviewed studies) is available on the clinical evidence page.
For Spravato programs
See how it looks for an esketamine patient
We’ll walk through a real 84-day patient trajectory in the dashboard and show you exactly how the alert system works.
Book a Demo